Symposium:
197. Addressing the Ambiguities in Clinical Antifungal Guidelines — A Case-Based Discussion
Saturday, October 29, 2016: 8:30 AM-10:00 AM
Room: La Nouvelle Orleans Ballroom
Co-organized with the IDSA Clinical Guidelines Committee

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • through a case study apply the appropriate guidelines for the management of patients with complicated invasive fungal infections
  • identify the appropriate diagnostic approach of patients with invasive fungal infections
  • update their knowledge basis on the standard of care for invasive fungal infections

Target Audience: Academicians, Clinicians, Fellows, HIV clinicians, HIV specialists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Members-in-training, Researchers

Tracks: Adult ID, HIV-STD-TB, Investigative ID

Moderators:  Eleftherios Mylonakis, MD, PhD, FIDSA, Rhode Island Hospital and Warren Alpert Medical School of Brown University and Jo-Anne Young, MD, University of Minnesota

Presentations:
8:30 AM
Controversies in Invasive Candidiasis
Carol A. Kauffman, MD, FIDSA, FSHEA

9:00 AM
Controversies in Coccidioidomycosis
Neil M. Ampel, MD, FIDSA

9:30 AM

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours .15 of pharmacy CE

ACPE Number: 0221-9999-16-287-L01-P

Disclosures:

E. Mylonakis, T2 Biosystems: Grant Investigator , Consulting fee and Research grant
Astellas Pharma: Consultant , Consulting fee and Research grant

J. A. Young, Astellas: Investigator , No personal benefit. The University of Minnesota is paid for activities related to study enrollment.
Merck: Investigator , No personal benefit. The University of Minnesota is paid for activities related to study enrollment.
Pfizer: Investigator , No personal benefit. The University of Minnesota is paid for activities related to study enrollment.

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.